The BCMA CAR mRNA encodes a chimeric antigen receptor (CAR) that specifically targets B-cell maturation antigen (BCMA) on malignant plasma cells. Upon transfection, this mRNA enables transient CAR expression in immune effector cells, allowing them to recognize and eliminate BCMA+ multiple myeloma cells. The CAR construct typically includes an anti-BCMA scFv, hinge and transmembrane regions, and intracellular signaling domains such as 4-1BB and CD3ζ for activation and persistence.
|
| Form | Liquid |
| Concentration | 1mg/mL |
| Full mRNA length | 1738 nt |
| Full mRNA Molecular Weight | 560055 Da |
| Storage buffer | 1mM Sodium citrate, pH 6.5 |
| Storage condition | Store at -20°C for short term (<3 months), store at -80°C for long term. |
| Appearance | Clear and free of foreign particles |
| RNA Length | Expected size band detected |
| RNA Content | Target ± 5% |
| Integrity | ≥ 75% |
| OD260/OD280 | 1.70 ~ 2.30 |
| Capping Efficiency | ≥ 90% |
| Endotoxin | < 10 EU/mg |
| pH | Target ± 0.5 |
| Jurkat cells were transfected with BCMA CAR mRNA formulated in lipid nanoparticles (LNPs) to enable efficient mRNA delivery and transient CAR expression. Following transfection, surface expression of the BCMA CAR on Jurkat cells was evaluated using a fluorescently labeled Fab antibody Alexa Fluor® 647-F(ab')2 Goat Anti-Mouse IgG, F(ab')2 specific to the CAR construct. This assay confirms successful mRNA translation and membrane localization of the BCMA CAR, validating the functionality of the LNP-delivered mRNA construct. Expression data was collected after 24hours. |
»
»
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.